Video
Dr. Ma on the METRIC Trial in Triple-Negative Breast Cancer
Author(s):
Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer.
Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer (TNBC).
The METRIC trial is a randomized study comparing glembatumumab vedotin (CDX-011), a gpNMB-targeted antibody-drug conjugate, with capecitabine in patients with metastatic TNBC.
Patients are being randomized in a 2:1 ratio to receive glembatumumab vedotin or capecitabine. The study is selecting patients who are positive for gpNMB, which is present in about 40% of TNBC cases. Initial preliminary data have shown that patients with TNBC may have longer progression-free survival when they have increased gpNMB expression.
